Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
11,181,416
-
Total 13F shares
-
31,710,905
-
Share change
-
+743,089
-
Total reported value
-
$52,000,995
-
Price per share
-
$1.64
-
Number of holders
-
53
-
Value change
-
+$1,135,340
-
Number of buys
-
12
-
Number of sells
-
31
Institutional Holders of Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) as of Q4 2024
As of 31 Dec 2024,
Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,710,905 shares.
The largest 10 holders included
Atlas Venture Life Science Advisors, LLC, Blue Owl Capital Holdings LP, BVF INC/IL, BML Capital Management, LLC, ORBIMED ADVISORS LLC, Omega Fund Management, LLC, GILEAD SCIENCES, INC., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., and NEA Management Company, LLC.
This page lists
53
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.